Trial Profile
PARP Inhibition After Preoperative Chemotherapy in Patients With Triple Negative Breast Cancer or ER/PR +, HER2 Negative With Known BRCA1/2 Mutations: Hoosier Oncology Group BRE09-146
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Rucaparib (Primary) ; Rucaparib (Primary) ; Cisplatin
- Indications Breast cancer; Male breast cancer; Triple negative breast cancer
- Focus Therapeutic Use
- 10 Feb 2020 Status changed from active, no longer recruiting to completed.
- 12 Jul 2018 Planned End Date changed from 1 Jun 2018 to 1 Dec 2018.
- 12 Jul 2018 Planned primary completion date changed from 1 Jun 2018 to 1 Dec 2018.